This is an HTML version of an attachment to the Official Information request 'Management of Dexamfetamine supply'.

 
 
 
 
 
 
 
15 March 2016 
 
Via email: fyi-request-3536-
[email address] 
 
  
 
 
Dear Anita 
 
 
 
REQUEST FOR INFORMATION 
 
Thank you for your request dated 11 January 2016 under the Official Information Act 
1982  (OIA) for information relating to  dexamfetamine.  Further to the information 
provided  to you on 15 February 2016, this letter deals with the remainder of our 
response. 
 
You asked for all the information PHARMAC holds on the current supply management 
issue for dexamfetamine, particularly the cause, management, mitigation and resolution 
of this issue.  
 
PHARMAC is releasing emails between our contract manager, the Ministry of Health and 
API (suppliers of dexamphetamine), which provide details around how the 
dexamphetamine stock situation was caused, managed, mitigated and resolved.  
 
I note that some content within the material provided to you has been redacted. We 
make these judgments carefully and have determined the redactions necessary to: 
 
  protect the privacy of natural persons (section 9(2)(a));  
  protect information where the making available of the information would be likely to 
unreasonably prejudice the commercial position of the person who supplied or who is 
the subject of the information (section 9(2)(b)(ii)); 
  protect information which is subject to an obligation of confidence or which any 
person has been or could be compelled to provide under the authority of any 
enactment, where the making available of the information would be likely to prejudice 
the supply of similar information, or information from the same source, and it is in the 
public interest that such information should continue to be supplied 
(section 9(2)(ba)(i)); 
  protect information which is subject to an obligation of confidence or which any 
person has been or could be compelled to provide under the authority of any 
enactment, where the making available of the information would be likely otherwise 
to damage the public interest (section 9(2)(ba)(ii)); 
  enable PHARMAC to carry out, without prejudice or disadvantage, commercial 
activities (section 9(2)(i)); and/or 
  enable PHARMAC to carry on, without prejudice or disadvantage, negotiations, 
including commercial negotiations (section 9(2)(j)). 
 
A108045 
 
 
 

 
As required under the OIA, we also considered whether, in the circumstances, the 
withholding of this information was outweighed by other considerations which render it 
desirable, in the public interest, to make this information available.  In this case we did 
not consider that the public interest outweighed the reasons for withholding the 
information.  Please note you have the right, by way of complaint under section 28(3) of 
the OIA to an Ombudsman, to seek an investigation and review of our decision. 
 
We trust that the provision of these documents answers your queries.  Please feel free to 
contact PHARMAC again if you have any further queries. 
 
 
 
Yours sincerely 
 
Peter Alsop 
Director, Engagement and Implementation 
 

Document Outline